Nonaka Tatsuki, Bunya Naofumi, Nakayama Ryuichi, Hagiwara Shunya, Uemura Shuji, Harada Keisuke, Narimatsu Eichi
Department of Emergency Medicine Sapporo Medical University Sapporo Japan.
Acute Med Surg. 2022 Feb 16;9(1):e737. doi: 10.1002/ams2.737. eCollection 2022 Jan-Dec.
Multisystem inflammatory syndrome in adults (MIS-A) is a postacute coronavirus disease 2019 (COVID-19) syndrome occurring weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although this hyperinflammatory syndrome causes significant morbidity, mortality is low. Reports of MIS-A following acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 infection have rarely been reported. We describe two cases of MIS-A that developed after recovery from critical acute COVID-19.
We present two cases of MIS-A. In both cases, approximately 4 weeks after the onset of COVID-19, the patients developed gastrointestinal disorders, complicated by other organ damage, and died.
ARDS and MIS-A can occur in a patient with COVID-19 at different times of onset. Clinicians should consider MIS-A when unexplained multisystemic abnormalities are noted after the treatment of ARDS due to COVID-19.
成人多系统炎症综合征（MIS-A）是一种在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染数周后出现的新型冠状病毒肺炎（COVID-19）后急性综合征。尽管这种高炎症综合征会导致显著的发病率，但死亡率较低。SARS-CoV-2感染导致急性呼吸窘迫综合征（ARDS）后发生MIS-A的报道很少。我们描述了两例在严重急性COVID-19康复后发生的MIS-A病例。
我们报告两例MIS-A病例。在这两例病例中，COVID-19发病约4周后，患者出现胃肠道疾病，并伴有其他器官损害，最终死亡。
ARDS和MIS-A可在COVID-19患者的不同发病时间出现。当COVID-19导致的ARDS治疗后出现无法解释的多系统异常时，临床医生应考虑MIS-A。
